Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CD70 Antibody (R3J48)

Catalog #:   RHE01902 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2b
Applications: IHC
Accession: P32970
Overview

Catalog No.

RHE01902

Species reactivity

Human

Host species

Mouse

Isotype

IgG2b

Clonality

Monoclonal

Tested applications

IHC: 1:20-1:100

Target

CD27 ligand, CD70, TNFSF7, CD27LG, CD27L, CD70 antigen, Tumor necrosis factor ligand superfamily member 7, CD27-L

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P32970

Applications

IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3J48

Data Image
  • Immunohistochemical
    IHC-P analysis of tonsil tissue by CD70 antibody (RHE01902). IHC-P was performed using sections of the formalin-fixed paraffin-embedded tonsil tissue;Result: Germinal center cells and non-germinal center cells are positively stained at the cell membrane and cytoplasm.
References

Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621

Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633

The CD70-CD27 axis in cancer immunotherapy: Predictive biomarker and therapeutic target., PMID:40388162

CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study., PMID:40306966

CD70-targeted cancer theranostics: Progress and challenges., PMID:40250430

CD70 recruitment to the immunological synapse is dependent on CD20 in B cells., PMID:40232798

Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease., PMID:40078987

CD8α and CD70 mark human natural killer cell populations which differ in cytotoxicity., PMID:40046047

Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics., PMID:40015924

A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells., PMID:39906740

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes., PMID:39867912

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030

Direct Inhibitory Effect of HTLV-1-Infected T Cells on the Production of Anti-Ro/SS-A Antibody by B Cells from Patients with Sjögren's Syndrome., PMID:39775490

A mechanistic, functional, and clinical perspective on targeting CD70 in cancer., PMID:39725151

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML., PMID:39571145

CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond., PMID:39570653

CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study., PMID:39510586

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD., PMID:39197208

Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer., PMID:38730739

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models., PMID:38646638

The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment., PMID:38637886

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma., PMID:38583184

ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study., PMID:38480552

Benzoic acid, 4-hydroxy-, methyl ester from Smilax zeylanica Linn emerges as a potent inhibitor of CD27/CD70 signaling pathway., PMID:38353477

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc., PMID:37965342

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study., PMID:37914483

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799

PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases., PMID:37696593

METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer., PMID:37648786

Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes., PMID:37371066

Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing., PMID:37361386

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056

Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models., PMID:37093350

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer., PMID:36970072

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia., PMID:36932256

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance., PMID:36787696

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy., PMID:36779592

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities., PMID:36745503

CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19., PMID:36537906

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment., PMID:36394119

Identification and characterization of blocking nanobodies against human CD70., PMID:36239354

Adenoviral delivery of soluble ovine OX40L or CD70 costimulatory molecules improves adaptive immune responses to a model antigen in sheep., PMID:36211974

When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders., PMID:36209991

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy., PMID:36100308

Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles., PMID:36095190

CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions., PMID:36091071

A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma., PMID:36055572

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes., PMID:35886899

Agonistic anti-CD27 antibody ameliorates EAE by suppressing IL-17 production., PMID:35856659

Datasheet

Document Download

Anti-CD70 Antibody (R3J48).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CD70 Antibody (R3J48) [RHE01902]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only